Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for Recurrent or Refractory Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 25 Jun 2018
At a glance
- Drugs Atezolizumab (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 14 Jun 2018 Status changed from not yet recruiting to recruiting.
- 01 Nov 2017 Planned initiation date changed from 15 Oct 2017 to 15 Dec 2017.